Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma

Paused · Phase 1

Conditions studied: Glioma

In brief

This is a pilot study to assess a new methodology developed for High Grade Glioma (HGG). FMISO PET (Fluoromisonidazole-PET) allows researchers to study whether tumor cells lack oxygen (hypoxia). FLT PET (Fluorodeoxythymidine-PET) allows researchers to study the increase in the number of cells as a result of cell growth and cell division (proliferation). Tumors that have low oxygen levels and/or are dividing fast shall resist to standard cancer treatment. The study will compare FMISO PET and FLT PET imaging techniques with molecular biomarkers of hypoxia, angiogenesis, and cellular proliferation in tissue. proliferation).This information could help researchers develop new treatment techniques to better treat cancer.

Key facts

Study ID

NCT04309552

Run by

Weill Medical College of Cornell University

People needed

8

Starts

2021-02-01

Expected to finish

2027-03-01

Last updated by the study team

2026-01-27

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female ≥ 18 years of age
• Documentation of a suspected HGG diagnosis based on clinical and MRI findings

You may not qualify if…

• Pregnant or breastfeeding
• Contraindications to receiving Positron Emission Tomography (PET) imaging (e.g. claustrophobia)

Where it is running

• Weill Cornell Medical College — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.